Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

NCT01897012 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01897012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01897012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
July 17, 2013
Completion date
November 30, 2018
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myc positive, recurrent b-cell non-hodgkin lymphoma, recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent hodgkin lymphoma, recurrent mantle cell lymphoma, recurrent mature t- and nk-cell non-hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, refractory hodgkin lymphoma, refractory mantle cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma